fda announcement tirzepatide TIRZEPATIDE: VERDICT, 📝Messages conveyed here are of my own understandings, views, and perceptions of the latest ruling. 📌 All points are subject to change based on FDA rulings and compliance with FDA Shortage and Semaglutide &

Phase II data showed the once-a-week injectable enabled 54 percent of participants to attain resolution of obesity.

2024 Mar 1;22(1):225

50 Real space and Rosetta refinements were carried out using Phenix software package

2009 Oct;19(5):426-31

Together, these findings underscore the power of personalized, continuous remote care to support durable and scalable weight loss outcomes #ObesityWeek #OW2025 #Obesity #Telemedicine #ClinicallyMeaningfulWeightLoss #GLP1 #IncretinMimetics #Realworld To view or add a comment, sign in Two new studies from Virta Health will be presented at Obesity Week 2025, highlighting the long-term and flexible impact of the Virta Intervention, a telemedicine-based approach focused on individualized nutrition and continuous remote care

however, they did note a strong placebo effect